Literature DB >> 9088955

VS38 immunostaining in neuroendocrine tumours.

S S Banerjee1, J H Shanks, P S Hasleton.   

Abstract

VS38 was originally described as a marker of neoplastic and non-neoplastic plasma cells. We recently described its immunoreactivity with melanocytic lesion. The aim of the present study was to investigate the reactivity of VS38 with various neuroendocrine tumours. Using paraffin sections of routinely processed archival tissue we found that 72% of 50 neuroendocrine tumours tested showed immunohistochemical positivity for VS38. A wide spectrum of neuroendocrine tumours were positive. Use of a panel of markers and awareness of the lack of specificity of VS38 will avoid misdiagnosis, particularly when neuroendocrine tumours and other lesions which react immunohistochemically with this antibody are located at unusual sites and exhibit plasmacytoid features.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088955     DOI: 10.1046/j.1365-2559.1997.d01-599.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  4 in total

1.  VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era.

Authors:  Shumpei Mizuta; Takahito Kawata; Hiroshi Kawabata; Noriko Yamane; Saya Mononobe; Takao Komai; Yusuke Koba; Naoya Ukyo; Akira Tamekane; Mitsumasa Watanabe
Journal:  Int J Hematol       Date:  2019-06-10       Impact factor: 2.490

Review 2.  Diffuse large B-cell lymphomas with plasmablastic differentiation.

Authors:  Julie Teruya-Feldstein
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

Review 3.  The histological diagnosis of metastases to the breast from extramammary malignancies.

Authors:  Andrew H S Lee
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

4.  Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions.

Authors:  E S Hookway; Z Orosz; Y Uchihara; A Grigoriadis; A B Hassan; U Oppermann; N A Athanasou
Journal:  Clin Sarcoma Res       Date:  2017-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.